Mechanism of Action of Crizotinib
Introduction Crizotinib is an oral targeted anticancer drug marketed under the brand name Xalkori. It belongs to the receptor tyrosine kinase inhibitor (TKI) class. Its major molecular targets are ALK (anaplastic lymphoma kinase), ROS1, and MET (c-Met/HGFR). The current Xalkori prescribing information also identifies RON (Recepteur d’Origine Nantais) among the receptor tyrosine kinases inhibited by … Read more